Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07258290 · ClinicalTrials.gov registry record · NA
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
A NA study, sponsored by Teleflex.
- Recruiting
- Registry status
- NA
- Development phase
- 1,859
- Enrollment target
NCT07258290: Recruiting NA study, sponsored by Teleflex.
NCT07258290 is a NA study that is actively recruiting participants, run by Teleflex. The registered enrollment target is 1,859 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07258290, a NA study, is actively recruiting participants, sponsored by Teleflex.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,859 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system
Primary Outcome
The primary endpoint is Target Lesion Failure (TLF) at 12 months, a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven target lesion revascularization (TLR).
Interventions
- DEVICE Freesolve RMS
- DEVICE Xience DES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,859 participants |
| Start Date | 2026-06-11 |
| Est. Completion | 2033-06 |
| Phase | NA |
What NCT07258290 shows while recruiting
NCT07258290 is an interventional study that assigns participants to a tested intervention. Its 1,859 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 2 interventions - of which Freesolve RMS is the first listed.
NCT07258290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07258290 about?
NCT07258290 is a clinical study titled "Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions". The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system
What is the current status of trial NCT07258290?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,859 participants. The study started on 2026-06-11. Estimated completion is 2033-06.
What interventions are being tested in trial NCT07258290?
The interventions under investigation include: Freesolve RMS (DEVICE), Xience DES (DEVICE).
Who is sponsoring clinical trial NCT07258290?
This trial is sponsored by Teleflex, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07258290's enrollment target sits among peer trials
1,859 56th of 2000 higher than 1,945 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI